Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: An open-label, single-dose, randomized, two-way crossover study in healthy chinese male volunteers

Clinical Therapeutics

Volumn 31, Issue 4, 2009, Pages 777-783

  Liu, Yun ^a   Jia, Jingying ^a   Liu, Gangyi ^a   Li, Shuijun ^a   Lu, Chuan ^a   Liu, Yanmei ^a   Yu, Chen ^a  

^a SHANGHAI XUHUI CENTRAL HOSPITAL   (China)

Author keywords

amlodipine; bioequivalence; LC MS MS; pharmacokinetics

Indexed keywords

AMLODIPINE BESYLATE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOEQUIVALENCE; BLOOD SAMPLING; BODY HEIGHT; BODY WEIGHT; CHINESE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POSITIVE ION ELECTROSPRAY; SIDE EFFECT; SINGLE DRUG DOSE; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; AMLODIPINE; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HALF-LIFE; HUMANS; MALE; TABLETS; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 65549153100     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.04.013     Document Type: Article

References (16)

1. Scholz H. Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther 10 Suppl 3 (1997) 869-872
2. McKeage K., and Siddiqui M.A. Amlodipine/atorvastatin fixed-dose combination: A review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. Am J Cardiovasc Drugs 8 (2008) 51-67
3. Walker D.K., Humphrey M.J., and Smith D.A. Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. Xenobiotica 24 (1994) 243-250
4. Luksa J., Josic D., Kremser M., et al. Pharmacokinetic behaviour of R-(+)- and S-(-)-amlodipine after single enantiomer administration. J Chromatogr B 703 (1997) 185-193
5. Carvalho M., Oliveira C.H., Mendes G.D., et al. Amlodipine bioequivalence study: Quantification by liquid chromatography coupled to tandem mass spectrometry. Biopharm Drug Dispos 22 (2001) 383-390
6. Park J.Y., Kim K.A., Lee G.S., et al. Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. Clin Ther 26 (2004) 715-723
7. Chung M., Calcagni A., Glue P., and Bramson C. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol 46 (2006) 1212-1216
8. Abad-Santos F., Novalbos J., Gálvez-Múgica M.A., et al. Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharmacol Res 51 (2005) 445-452
9. State Food and Drug Administration of China. Guideline for Good Clinical Principles [SFDA Web site]. Accessed August 6, 2003. http://www.sda.gov.cn/WS01/CL0053/24473.html
10. World Medical Association Declaration of Helsinki (WMA). Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly (October 7, 2000). http://www.wma.net/e/policy/b3.htm [WMA Web site]. Accessed September 20, 2007
11. European Agency for the Evaluation of Medicinal Products (EMEA), International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH topic E 6 (2002), WHO, Geneva, Switzerland. http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf (R1), Accessed September 26, 2007
12. Shumaker R.C. PKCALC: A BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 17 (1986) 331-348
13. Nirogi R.V., Kandikere V.N., Mudigonda K., et al. Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. Biomed Chromatogr 20 (2006) 833-842
14. Rhim S.Y., Park J.H., Park Y.S., et al. Bioequivalence and phar-macokinetic evaluation of two branded formulations of aceclofenac 100 mg: A single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. Clin Ther 30 (2008) 633-640
15. Vincent J., Harris S.I., Foulds G., et al. Lack of effect of grapefruit juice on the pharmacokinetics and pharmaco-dynamics of amlodipine. Br J Clin Pharmacol 50 (2000) 455-463
16. Pico J.C., Domínguez G., Negri A.L., et al. Comparative pharmacokinetics of a single oral dose of two formulations of amlodipine. A randomized, single-blind, two-period, two-sequence, crossover study. Arzneimittelforschung 58 (2008) 323-327